NDAINJECTIONINJECTABLE
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Mechanism of Action
properties. It acts by enhancing the inhibition of Factor Xa and thrombin by antithrombin. In humans, dalteparin potentiates preferentially the inhibition of coagulation Factor Xa, while only slightly affecting the activated partial thromboplastin time (APTT).
Indications (7)
non-Q-wave myocardial infarction () • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgeryhip replacement surgerymedical patients with severely restricted mobility during acute illness () • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancernon-Q-wave myocardial infarctiondeep vein thrombosis (DVT)symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in pediatric patients from birth (gestational age at least 35 weeks)symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ()
Clinical Trials (5)
Use Of Fragmin In Hemodialysis
Started Oct 2013
152 enrolled
Chronic Renal Failure
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Started Aug 2009
38 enrolled
Venous Thromboembolism
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
Started Oct 2008
62 enrolled
Diabetic Foot Ulcer
Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
Started Apr 2008
276 enrolled
Diabetic Foot Ulcer
Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients
Started Jun 2007
102 enrolled
Acute Deep Vein Thrombosis